within Pharmacolibrary.Drugs.ATC.L;

model L04AX04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.93,
    Cl             = 0.00014333333333333334,
    adminDuration  = 600,
    adminMass      = 25 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.075,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.018333333333333333,
    Tlag           = 10.020000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L04AX04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Lenalidomide is an immunomodulatory drug used primarily for the treatment of multiple myeloma and certain myelodysplastic syndromes. It is an oral derivative of thalidomide and is currently approved for use in several countries for these indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters observed in adult patients (both sexes) with multiple myeloma after a single oral dose under fasting conditions.</p><h4>References</h4><ol><li><p>Chen, N, et al., &amp; Palmisano, M (2017). Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide. <i>Clinical pharmacokinetics</i> 56(2) 139–152. DOI:<a href=\"https://doi.org/10.1007/s40262-016-0432-1\">10.1007/s40262-016-0432-1</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27351179/\">https://pubmed.ncbi.nlm.nih.gov/27351179</a></p></li><li><p>Richardson, PG, et al., &amp; Bahlis, NJ (2023). Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma. <i>The New England journal of medicine</i> 389(11) 1009–1022. DOI:<a href=\"https://doi.org/10.1056/NEJMoa2303194\">10.1056/NEJMoa2303194</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37646702/\">https://pubmed.ncbi.nlm.nih.gov/37646702</a></p></li><li><p>Chen, N, et al., &amp; Kumar, G (2012). Pharmacokinetics, metabolism and excretion of [(14)C]-lenalidomide following oral administration in healthy male subjects. <i>Cancer chemotherapy and pharmacology</i> 69(3) 789–797. DOI:<a href=\"https://doi.org/10.1007/s00280-011-1760-3\">10.1007/s00280-011-1760-3</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22037879/\">https://pubmed.ncbi.nlm.nih.gov/22037879</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L04AX04;
